BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 10864195)

  • 1. Immune selection in neoplasia: towards a microevolutionary model of cancer development.
    Pettit SJ; Seymour K; O'Flaherty E; Kirby JA
    Br J Cancer; 2000 Jun; 82(12):1900-6. PubMed ID: 10864195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immune system--is it relevant to cancer development, progression and treatment?
    Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy.
    Bhutia SK; Mallick SK; Maiti TK
    Cell Biol Int; 2010 Apr; 34(5):553-63. PubMed ID: 20384587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
    Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
    Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.
    Mapara MY; Sykes M
    J Clin Oncol; 2004 Mar; 22(6):1136-51. PubMed ID: 15020616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immune response and cancer].
    El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
    Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
    Zou W
    Nat Rev Cancer; 2005 Apr; 5(4):263-74. PubMed ID: 15776005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor-induced immunosuppression].
    Paul S; Calmels B; Régulier E
    Ann Biol Clin (Paris); 2002; 60(2):143-52. PubMed ID: 11937439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
    Mocellin S; Nitti D
    Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current concepts in immunotherapy for the treatment of colorectal cancer.
    Indar A; Maxwell-Armstrong CA; Durrant LG; Carmichael J; Scholefield JH
    J R Coll Surg Edinb; 2002 Apr; 47(2):458-74. PubMed ID: 12018689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virus-based immunotherapy of cancer: what do we know and where are we going?
    Sørensen MR; Thomsen AR
    APMIS; 2007 Nov; 115(11):1177-93. PubMed ID: 18092950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressive influences in the immune response to cancer.
    Bronte V; Mocellin S
    J Immunother; 2009 Jan; 32(1):1-11. PubMed ID: 19307988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging strategies in regulatory T-cell immunotherapies.
    Gajewski TF; Chesney J; Curriel TJ
    Clin Adv Hematol Oncol; 2009 Jan; 7(1):1-10; quiz 11-2. PubMed ID: 19288606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour immunotherapy: the adjuvant treatment of the 21st century?
    Bremers AJ; Kuppen PJ; Parmiani G
    Eur J Surg Oncol; 2000 Jun; 26(4):418-24. PubMed ID: 10873365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tumours by adoptive transfer of immune cells.
    Macary PA; Too CT; Dai X
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):569-74. PubMed ID: 16700896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic instability and darwinian selection in tumours.
    Cahill DP; Kinzler KW; Vogelstein B; Lengauer C
    Trends Cell Biol; 1999 Dec; 9(12):M57-60. PubMed ID: 10611684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.